Effect of neutral endopeptidase inhibition on vascular response induced by exogenous angiotensin in the isolated rat lung

Polish Journal of Pharmacology

Volumn 55, Issue 6, 2003, Pages 1071-1078

  Bartuś, Joanna B ^a   Chłopicki, Stefan ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Angiotensin 1 7; Angiotensin converting enzyme; Angiotensin I; Angiotensin II; Isolated lung; Neutral endopeptidase

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; BICARBONATE; BRADYKININ ANTAGONIST; BRADYKININ RECEPTOR; BUFFER; CALCIUM CHLORIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; ICATIBANT; LOSARTAN; MAGNESIUM SULFATE; PERINDOPRILAT; PHOSPHATE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; THIORPHAN; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; BLOOD VESSEL REACTIVITY; BREATHING; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE SYNTHESIS; ISOLATED LUNG; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG PERFUSION; LUNG VASOCONSTRICTION; LUNG WEIGHT; NONHUMAN; RAT;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; IMIDAZOLES; INDOLES; LOSARTAN; LUNG; NEPRILYSIN; PEPTIDE FRAGMENTS; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, BRADYKININ; THIORPHAN; TIME FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 1642421108     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Abbas A., Gorelik G., Carbini L., Scicli A.: Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension, 1997, 30, 217-221.
2. Bakhle Y.S., Reynard A.M., Vane J.R.: Metabolism of the angiotensins in isolated perfused tissues. Nature, 1969, 222, 956-959.
3. Campbell D.: The renin-angiotensin and the kalli-krein-kinin systems. Int. J. Biochem. Cell Biol., 2003, 35, 784-791.
4. Campbell D., Kladis A.: Duncan A. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension, 1994, 23, 439-449.
5. Chappell M., Brosnihan K., Diz D., Ferrario C.: Identification of angiotensin-(1-7) in rat brain. Evidence for differential processing of angiotensin peptides. J. Biol. Chem., 1989, 264, 16518-16523.
6. Chappell M., Tallant E., Brosnihan K., Ferrario C.: Processing of angiotensin peptides by NG108-15 neuroblastoma x glioma hybrid cell line. Peptides, 1990, 11, 375-380.
7. Davie A., McMurray J.: Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension, 1999, 34, 457-460.
8. Donoghue M., Hsieh F., Baronas E., Gotbout K., Gosselin M., Stagliano N.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res., 2000, 87, 523-525.
9. Ferrario C.: Does angiotensin-(1-7) contribute to cardiac adaptation and preservation of endothelial function in heart failure? Circulation, 2002, 105, 1523-1525.
10. Ferrario C., Chappell M., Tallant E., Brosnihan K., Diz D.: Counterregulatory actions of angiotensin-(1-7). Hypertension, 1997, 30, 535-541.
11. Gavras H., Brunner H.: Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertension, 2001, 37, 342-345.
12. Halkin A., Keren G.: Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Amer. J. Med., 2002, 112, 126-134.
13. Hecker M., Porsti I., Busse R.: Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors. Braz. J. Med. Biol. Res., 1994, 27, 1917-1921.
14. Heitsch H., Brovkovych S., Malinski T., Wiemer G.: Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension, 2001, 37, 72-76.
15. Hoshida S., Kato J., Nishino M., Egarni Y., Takeda T., Kawabata M.: Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation, 2001, 103, 630-633.
16. Kohara K., Brosnihan K., Chappell M., Khosla M., Ferrario C.: Angiotensin-(1-7). A member of circulating angiotensin peptides. Hypertension, 1991, 17, 131-138.
17. Kucharewicz I., Pawlak R., Matys T., Chabielska E., Buczko W.: Angiotensin-(1-7): an active member of the renin-angiotensin system. J. Physiol. Pharmacol., 2002, 53, 533-540.
18. Kucharewicz I., Pawlak R., Matys T., Pawlak D., Buczko W.: Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension, 2002, 40, 774-779.
19. Loot A., Roks A.J., Henning R.A., Tior A., Suurmeijer A.J., Boomsma F., van Gilst W.H.: Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation, 2002, 105, 1548-1550.
20. Mahon J., Carr R., Nicol A., Henderson I.: Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor. J. Hypertension, 1994, 12, 1377-1381.
21. McMurray J., Davie A.: Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation, 2002, 106, e147.
22. Muthalif M., Benter I., Uddin M., Harper J., Malik K.: Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J. Pharmacol. Exp. Ther., 1998, 284, 388-398.
23. Oliveira M., Fortes Z., Santos R., Kosla M., De Carvalho M.: Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides, 1999, 20, 1195-1201.
24. Pieruzzi F., Abassi Z., Keiser H.: Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation, 1995, 92, 3105-3112.
25. Porsti I., Bara A., Busse R., Hecker M.: Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Brit. J. Pharmacol., 1994, 111, 652-654.
26. Roks A.J., van Geel P.P., Pinto Y.M., Burkema H., Hrnning R.H., de Zeuw D., van Gilst W.H.: Angioten-sin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension, 1999, 34, 296-301.
27. Santos R., Brosnihan K., Jacobsen D., DiCorleto P., Ferrario C.: Production of angiotensin-(1-7) by human vascular endothelium. Hypertension, 1992, 19, Suppl. 2., II56-II61.
28. Tipnis S.M., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J.: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem., 2000, 275, 33238-33243.
29. Uhlig S., Heiny O.: Measuring the weight of the isolated perfused rat lung during negative pressure ventilation. J. Pharmacol. Toxicol. Method., 1995, 33, 147-152.
30. Vane J.: The history of inhibitors of angiotensin converting enzyme. J. Physiol. Pharmacol., 1999, 50, 489-498.
31. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J.: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem., 2002, 277, 14838-14843.
32. Widdop R., Sampey D., Jarrott B.: Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. Hypertension, 1999, 34, 964-968.
33. Yagil Y., Yagil C.: Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension, 2003, 41, 871-873.
34. Yamada K., Iyer S., Chappell M., Ganten D., Ferrario C.: Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension, 1998, 32, 496-502.
35. Yamamoto K., Chappell M., Brosnihan K., Ferrario C.: In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension, 1992, 19, 692-696.